Biotech Black Box

//Biotech Black Box

Looking Inside the Biotech Black Box (Part 16)

By | December 14th, 2015|Analysis, Biotech Black Box, Blog|

Some Market Data (1) The global pharmaceutical market should hit [...]

Looking Inside the Biotech Black Box (Part 15)

By | August 28th, 2015|Analysis, Biotech Black Box, Blog|

Market Exclusivity – Product Life-Cycle Management Market exclusivity is a [...]

Looking Inside the Biotech Black Box (Part 14)

By | August 7th, 2015|Analysis, Biotech Black Box, Blog|

Market Exclusivity – Regulatory Data Market exclusivity is a critical [...]

Looking Inside the Biotech Black Box (Part 13)

By | July 17th, 2015|Analysis, Biotech Black Box, Blog|

Market Exclusivity – Patents Market exclusivity is a critical component [...]

Looking Inside the Biotech Black Box (Part 12)

By | July 3rd, 2015|Analysis, Biotech Black Box, Blog|

Some pharmaceutical industry history (1) The success rate for new [...]

Looking Inside the Biotech Black Box (Part 11)

By | June 19th, 2015|Analysis, Biotech Black Box, Blog|

Cost-Effectiveness and Affordability of New Medicines (4) Can individuals, healthcare [...]

Looking Inside the Biotech Black Box (Part 10)

By | June 5th, 2015|Analysis, Biotech Black Box, Blog|

Cost-Effectiveness and Affordability of New Medicines (3) The cost-effectiveness of [...]

Looking Inside the Biotech Black Box (Part 9)

By | May 22nd, 2015|Analysis, Biotech Black Box, Blog|

Cost-Effectiveness and Affordability of New Medicines (2) “Is the new [...]

Looking Inside the Biotech Black Box (Part 8)

By | May 8th, 2015|Analysis, Biotech Black Box, Blog|

Cost-Effectiveness and Affordability of New Medicines (1) There were 5,408 [...]

Looking Inside the Biotech Black Box (Part 7)

By | April 24th, 2015|Analysis, Biotech Black Box, Blog|

Theratechnologies Case Study – was tesamorelin (EGRIFTA™) a success? In [...]